Lung cancer pharmacogenetics

Kawajiri K, Watanabe J, Eguchi H, Nakachi K, Kiyohara C, Hayashi S. Polymorphisms of human Ah receptor gene are not involved in lung cancer. Pharmacogenetics 1995 5(3) 151—158. 

K. Suemasu, Y. Higashi et al. (2000). Association of CYPIBI genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics 10, 25-33. 

Hirvonen, A., K. Husgafvel-Pursiainen, S. Anttila, A. Karjalainen, M. Sorsa, and H. Vainio (1992). Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer. Pharmacogenetics 2, 259-263. 

Q.Y. Yue, M.L. Dahl, L. Bertilsson et al. (1992). Genetic polymorphism of cytochromes P450 Interethnic differences and relationship to incidence of lung cancer. Pharmacogenetics 2, 264-271. 

Kiyohara, C., Nakanishi, Y., Inutsuka, S., Takayama, K., Hara, N., Motohiro, A., Tanaka, K., Kono, S. and Hirohata, T. (1998) The relationship between CYP1A1 aryl hydrocarbon hydroxylase activity and lung cancer in a Japanese population. Pharmacogenetics, 8 (4), 315-323. 

Saarikoski ST, Reinikainen M, Antilla S, et al. 2000. Role of NAT2 deficiency in susceptibility to lung cancer among asbestos-exposed individuals. Pharmacogenetics 10 183-185. 

Loriot, M.A., S. Rebuissou, M. Oscarson, S. Cenee, M. Miyamoto, N. Ariyoshi et al. (2001). Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. Pharmacogenetics 11, 39 4. 

Rostami-Hodjegan, A., M.S. Leonard, H.F. Woods, and G.T. Tucker (1998). Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson s disease. Pharmacogenetics 8, 227-238. 

Risch A, Wikman H, Thiel S. et al. Glutathione-S-transferase Ml, M3, T1 and PI polymorphisms and susceptibility to non-small-cell lung cancer subtypes and hamartomas. Pharmacogenetics 2001 ll(9) 757-764. 

---